DNLI Stock Overview
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.
Denali Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$24.72|
|52 Week High||US$79.70|
|52 Week Low||US$20.24|
|1 Month Change||-9.25%|
|3 Month Change||-24.13%|
|1 Year Change||-58.03%|
|3 Year Change||19.25%|
|5 Year Change||n/a|
|Change since IPO||15.25%|
Recent News & Updates
|DNLI||US Biotechs||US Market|
Return vs Industry: DNLI underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: DNLI underperformed the US Market which returned -12.9% over the past year.
|DNLI Average Weekly Movement||9.8%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: DNLI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: DNLI's weekly volatility (10%) has been stable over the past year.
About the Company
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson’s disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer’s disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus.
Denali Therapeutics Fundamentals Summary
|DNLI fundamental statistics|
Is DNLI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DNLI income statement (TTM)|
|Cost of Revenue||US$291.24m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.32|
|Net Profit Margin||-344.79%|
How did DNLI perform over the long term?See historical performance and comparison
Is Denali Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DNLI ($24.72) is trading below our estimate of fair value ($51.25)
Significantly Below Fair Value: DNLI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DNLI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: DNLI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DNLI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DNLI is overvalued based on its PB Ratio (3.3x) compared to the US Biotechs industry average (1.5x).
How is Denali Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNLI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNLI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNLI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNLI's revenue (50.8% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: DNLI's revenue (50.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DNLI is forecast to be unprofitable in 3 years.
How has Denali Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DNLI is currently unprofitable.
Growing Profit Margin: DNLI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DNLI is unprofitable, and losses have increased over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare DNLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: DNLI has a negative Return on Equity (-31.13%), as it is currently unprofitable.
How is Denali Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: DNLI's short term assets ($988.4M) exceed its short term liabilities ($341.2M).
Long Term Liabilities: DNLI's short term assets ($988.4M) exceed its long term liabilities ($61.7M).
Debt to Equity History and Analysis
Debt Level: DNLI is debt free.
Reducing Debt: DNLI has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNLI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DNLI has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 24.2% each year
What is Denali Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DNLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DNLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DNLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DNLI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DNLI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ryan Watts (45 yo)
Dr. Ryan J. Watts, Ph.D. is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since August 2015. Dr. Watts has been a Director of Denali Therapeutics Inc. si...
CEO Compensation Analysis
Compensation vs Market: Ryan's total compensation ($USD12.67M) is above average for companies of similar size in the US market ($USD6.86M).
Compensation vs Earnings: Ryan's compensation has increased whilst the company is unprofitable.
Experienced Management: DNLI's management team is considered experienced (3.8 years average tenure).
Experienced Board: DNLI's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DNLI insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Denali Therapeutics Inc.'s employee growth, exchange listings and data sources
- Name: Denali Therapeutics Inc.
- Ticker: DNLI
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$3.039b
- Shares outstanding: 122.95m
- Website: https://www.denalitherapeutics.com
Number of Employees
- Denali Therapeutics Inc.
- 161 Oyster Point Boulevard
- 2nd Floor
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.